Highly Active Antiretroviral Therapy (HAART)

Subscribe to Selected New Research on Highly Active Antiretroviral Therapy

4525 relevant articles (451 outcomes, 523 trials/studies) found for this Therapy

Description: Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.

Also Known As:

HAART; Antiretroviral Therapy, Highly Active

Relationship Network

Therapy Context: Research Results

Therapeutics: 5215

Drug Therapy: 116820

Combination Drug Therapy: 8327

Highly Active Antiretroviral Therapy: 4525

Experts

1.	Hung, Chien-Ching: 15 articles (05/2008 - 03/2002)
2.	Manfredi, Roberto: 14 articles (10/2006 - 02/2002)
3.	Tirelli, Umberto: 13 articles (07/2008 - 09/2002)
4.	Chang, Shan-Chwen: 13 articles (05/2008 - 03/2002)
5.	Antinori, Andrea: 13 articles (02/2008 - 03/2002)
6.	Chen, Mao-Yuan: 12 articles (05/2008 - 03/2002)
7.	Bower, Mark: 12 articles (03/2008 - 03/2002)
8.	Chiodo, Francesco: 12 articles (01/2006 - 02/2002)
9.	Nelson, Mark: 11 articles (03/2008 - 03/2002)
10.	Tirelli, U: 11 articles (06/2007 - 07/2000)

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS) 06/01/2008 - "The introduction of highly active antiretroviral therapy (HAART) has dramatically improved the prognosis for individual patients with AIDS, but it has been education and a changing attitude to condoms that has led to a progressive fall in incidence, so that the worst of the epidemic may now be over" 06/19/2007 - "HAART has decreased the incidence of AIDS and death among HIV-infected individuals dramatically" 03/01/2007 - "Highly active antiretroviral therapy (HAART), a combination of at least three antiretroviral drugs, has dramatically improved the prognosis of HIV/AIDS" 07/01/2006 - "HAART has dramatically improved survival and quality of life among people living with HIV and AIDS globally" 10/01/2004 - "With the introduction of highly efficacious HAART therapy for HIV/AIDS successful long-term therapy became available" Order ALL the reference details at left...
2.	HIV Infections (HIV Infection) 05/01/2004 - "STUDY OBJECTIVES: The use of highly active antiretroviral therapy (HAART) has dramatically improved morbidity and mortality in patients with HIV infection" 06/01/2007 - "Highly active antiretroviral treatment (HAART) has revolutionized the HIV treatment, leading to a significantly decreased morbidity, prolonged survival, and an overall better outcome of HIV infection" 05/01/2004 - "The prognosis of HIV infection has improved dramatically since the introduction of highly active antiretroviral therapy (HAART)" 01/01/2004 - "The introduction of highly active anti-retroviral therapy (HAART) for Human Immunodeficiency Virus (HIV) infection has significantly improved the life expectancy of HIV positive patients" 01/01/2004 - "Highly active antiretroviral therapy (HAART) has dramatically reduced mortality from HIV infection, transforming it in many cases to a chronic condition" Order ALL the reference details at left...
3.	Infection 12/15/2007 - "MOTIVATION: Highly Active AntiRetroviral Therapies (HAART) can prolong life significantly to people infected by HIV since, although unable to eradicate the virus, they are quite effective in maintaining control of the infection" 11/01/2005 - "With the advent of highly active antiretroviral therapy (HAART), morbidity and mortality associated with HIV-1 infection have been dramatically reduced" 08/01/2005 - "The availability of highly active antiretroviral therapies (HAART) has not eliminated HIV-1 infection of the central nervous system (CNS) or the occurrence of HIV-associated neurological problems" 05/01/2001 - "The absence of antibody response after the initial remission of parvovirus B19 infection suggested that cellular immunity was an important component of reconstituted immune function against B19 after the patient received HAART" 09/01/2003 - "Combined with the high prevalence of cervical HPV infection and CIN, current data suggest that CIN should be aggressively sought and treated in HIV-positive women, including those who have responded well to HAART with good HIV viral load suppression and increasing CD4+ levels." Order ALL the reference details at left...
4.	Opportunistic Infections (Opportunistic Infection) 01/01/2005 - "A marked decrease in incidence has been observed for most central nervous system (CNS) opportunistic infections (OIs) after the use of highly active antiretroviral therapy (HAART) in developed countries" 06/01/2004 - "In industrialised countries, the use of Highly Active AntiRetroviral Therapy (HAART) results to be effective in suppressing the HIV viral load, with a quantitative and qualitative improvement in the CD4+ T-cell count followed by a strong reduction of opportunistic infections including those caused by parasites" 05/01/2004 - "However, the introduction in 1996 of highly active antiretroviral therapy as a standard of care for those infected with HIV-1 determined a strong protection against the development of opportunistic infections, as well as a remission of pre-existing complications, including KS" 04/01/2003 - "The use of highly active antiretroviral therapy (HAART) has led to a substantial decrease in the frequency of opportunistic infections among HIV-infected individuals, along with a significant reduction in their mortality rate" 11/01/1997 - "The use of highly active antiretroviral therapy (HAART) can be effective for reducing the first onset of opportunistic infections (OIs) and preventing their recurrence" Order ALL the reference details at left...
5.	Neoplasms (Cancer) 05/01/2008 - "The outcome for HIV-infected patients with cancer has dramatically improved in the highly active antiretroviral therapy (HAART) era, probably due to improvements in immune status and bone marrow function that allow the possibility of increased drug-dose intensity with a higher complete remission rate" 03/01/2007 - "CONCLUSION: The introduction of HAART has dramatically reduced the amount spent on chemotherapy due to a decreased incidence of AIDSrelated cancers, even though the individual patient treatments have become more effective and expensive." 01/01/2007 - "CONCLUSION: Dramatically reduced cancer rates were observed only in the late HAART period in parallel to the increasing proportion of children receiving HAART therapy." 09/01/2006 - "CONCLUSIONS: The introduction of HAART has dramatically reduced the incidence of KS and NHL and improved survival from these cancers for most patients in HIV care" 02/01/2002 - "Two cases of cervical dysplasia in HIV-infected women are presented, one from the pre-HAART era, who subsequently developed invasive cervical cancer and died, and one in whom HAART was used with good outcome" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Protease Inhibitors (Protease Inhibitor)
2.	cidofovir (Vistide)
3.	RNA (Ribonucleic Acid)
4.	Carbon Monoxide
5.	rituximab (Mabthera)
6.	Reverse Transcriptase Inhibitors
7.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
8.	DNA (Deoxyribonucleic Acid)
9.	Lamivudine (3TC)
10.	Zidovudine (Retrovir)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Transplants (Transplant)
5.	Stem Cell Transplantation

Best Treatments:
Research Summary Report
on Acquired Immunodeficiency Syndrome

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1237 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>